Latigo Biotherapeutics (NASDAQ:LTGO) Stock Rating Upgraded by Wall Street Zen

Latigo Biotherapeutics (NASDAQ:LTGO) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Latigo Biotherapeutics Stock Performance

LTGO stock opened at $19.49 on Friday. Latigo Biotherapeutics has a fifty-two week low of $17.22 and a fifty-two week high of $22.47.

Insider Transactions at Latigo Biotherapeutics

In other Latigo Biotherapeutics news, Director James B. Tananbaum purchased 140,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the transaction, the director owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the purchase, the insider directly owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.